Allogene Therapeutics to Highlight CAR T Access Research, Physician Panel and ALPHA3 Trial at ASH 2026
Allogene Therapeutics, Inc. (ALLO) will host an event at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026, to discuss challenges and opportunities in CAR T therapy delivery for large B-cell lymphoma. The event will feature new market research on barriers to CAR T access and a physician panel, alongside a showcase of the pivotal ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) as an MRD-guided therapy. The company aims to broaden CAR T adoption by bringing it earlier in treatment and expanding its delivery locations.
Allogene Therapeutics presents investigational pipeline and corporate strategy at London conference
Allogene Therapeutics' CEO, Zachary Roberts, MD, PhD, provided an update on the company's investigational drug pipeline and corporate strategy at the UBS Global Biopharma Conference in London. The company is actively developing cell therapies for cancer and other conditions and has previously shared an interim futility analysis for its ALPHA3 program and an expansion of its allogeneic CART portfolio at SITC2026. The presentation replay is available on Allogene's website.
Form 8K Allogene Therapeutics Inc For: 5 November By Investing.com
This article reports on the filing of a Form 8K by Allogene Therapeutics Inc., detailing the event for November 5th. The filing is provided by Investing.com, a financial markets news source. The stock symbol for Allogene Therapeutics Inc. is ALLO, which saw an 8.40% decline.
Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q3 EPS
Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced its Q3 EPS of ($0.15), which matched the analyst estimate. The report indicates that the company's financial performance for the quarter was precisely in line with market expectations. Investors can find further earnings history and related data on the company's StreetInsider.com page.
Allogene Therapeutics 3Q 2026: Revenue $0, EPS ($0.15) — 10-Q Summary
Allogene Therapeutics (ALLO) reported no collaboration revenue in the third quarter of 2026, consistent with the prior year. The company's net loss widened due to increased research and development spending, while diluted EPS improved to ($0.15) from ($0.19) year-over-year. Allogene expects its cash, cash equivalents, and investments of $388.9 million to fund operations into the first quarter of 2029.
Allogene Therapeutics Q3FY26 Results: ALPHA3 enrollment accelerates
Allogene Therapeutics reported its Q3 2026 financial results, highlighting accelerating enrollment in its ALPHA3 trial for MRD-positive lymphoma and promising early safety data for ALLO-329 in autoimmune diseases. The company is focusing on making CAR T therapies more accessible in community settings and announced the retirement of CFO Jeff Parker, with Annie Yoshiyama stepping in as interim financial lead. Allogene plans to present the first clinical results for ALLO-329 at the American College of Rheumatology Annual Meeting.
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported its Q3 2026 financial results, ending the quarter with $388.9 million in cash, cash equivalents, and investments, projecting a cash runway into 2029. The company provided updates on its pivotal Phase 2 ALPHA3 program for cema-cel in large B-cell lymphoma, with enrollment momentum continuing and a next clinical update anticipated in mid-2027. Additionally, Allogene announced updated results from its Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease, to be presented at ACR Convergence, highlighting emerging safety and clinical activity.
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported its third-quarter 2026 financial results, highlighting ongoing progress in its pivotal Phase 2 ALPHA3 program for cema-cel in large B-cell lymphoma, with enrollment momentum continuing and a next clinical update expected in mid-2027. The company also provided updates on its ALLO-329 program for autoimmune disease, with new data to be presented at ACR Convergence, and showcased its next-generation Dagger® technology pipeline. Allogene ended the quarter with $388.9 million in cash, projecting a cash runway into 2029.
Allogene Therapeutics, Inc. (ALLO) stock price, news, quote and history
Allogene Therapeutics, Inc. (ALLO) stock closed at $1.09, down 8.40%, with an after-hours price of $1.07. The clinical-stage immuno-oncology company focuses on developing allogeneic CAR T cell therapies for cancer and autoimmune diseases, including candidates targeting LBCL, RCC, and various autoimmune conditions. The company's Q3 2026 earnings call was scheduled for today, November 5th, at 5 PM GMT-5, and analysts have an average 1-year target estimate of $9.00 for the stock.
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
Allogene Therapeutics announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, presenting clinical progress in solid tumors and its broader vision for CAR T therapies. The company showcased a preclinical poster on a next-generation DLL3/CD70 dual CAR T product candidate for small cell lung cancer and other neuroendocrine tumors, highlighting the continued innovation with its Dagger® technology. These presentations emphasize Allogene's commitment to expanding patient access and transforming care across oncology and autoimmune diseases with its off-the-shelf CAR T platform.
Allogene Therapeutics (ALLO) Stock Price, Chart & Analysis
This article provides a comprehensive analysis of Allogene Therapeutics (ALLO) stock, detailing its current price, market capitalization, and key financial figures. It highlights the company's weak quality score, lack of dividend, and shrinking revenue, while noting its strong balance sheet with more cash than debt. The analysis also includes a "Belegger score" based on Buffett and Lynch methods, valuation insights, and various growth scenarios.
Allogene Therapeutics, Inc. (ALLO) Seasonal returns chart
This article provides a seasonal returns chart for Allogene Therapeutics, Inc. (ALLO), showing the average monthly price return from 2018 to 2026. The information is presented by Yahoo Finance, detailing the stock's performance and offering historical seasonality data.
Allogene Therapeutics, Inc. (ALLO) Seasonal Returns Chart - Yahoo Finance
The Yahoo Finance page for Allogene Therapeutics, Inc. (ALLO) reports that seasonality data is currently unavailable for the stock. As of the market close on October 30, ALLO's price was $1.18, down 5.60%, with a slight recovery of 1.69% in after-hours trading. The page also displays general market data for Canadian, US, European, and Asian markets, along with various financial indices and commodities.
Allogene schedules Q3 results and autoimmune therapy data release
Allogene Therapeutics (NASDAQ:ALLO) announced it will release its third-quarter 2026 financial results on November 5, 2026, after market close. Additionally, the company will host a webinar on November 9, 2026, to present preliminary safety and efficacy data from its Phase 1 RESOLUTION study for ALLO-329, an investigational allogeneic CAR T therapy for autoimmune diseases like lupus, myositis, and scleroderma. This data will also be presented at the American College of Rheumatology annual meeting.
Allogene Therapeutics Announces November Investor Events
Allogene Therapeutics (Nasdaq: ALLO) announced two investor events for November 2026. The company will report Q3 2026 financial results and provide a business update on November 5, followed by a live audio webcast. Additionally, Allogene will host a webinar on November 9 to review preliminary safety and efficacy data from its Phase 1 RESOLUTION study of ALLO-329 for autoimmune diseases, coinciding with a poster presentation at ACR Convergence 2026.
BlackRock reports more than 5% ownership of Allogene Therapeutics (ALLO).
BlackRock, Inc. has reported a beneficial ownership of 23,211,736 shares of Allogene Therapeutics, Inc. (ALLO) common stock, representing 6.7% of the class, as of September 30, 2026. The filing indicates that while BlackRock controls these shares, no single individual's interest within its various business units exceeds 5% of Allogene's outstanding common shares. This disclosure, made via an amended SCHEDULE 13G/A, details BlackRock's sole voting power over 22,733,488 shares and sole dispositive power over 23,211,736 shares.
Allogene Therapeutics to present at major investor conferences in Nov-Dec 2026
Allogene Therapeutics, a biotech company, announced its participation in three major investor conferences in November and December 2026: the UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Piper Sandler Healthcare Conference. The company will provide live webcasts and replays, updating investors on its progress in developing allogeneic CAR T therapies for cancer and autoimmune diseases. This engagement reflects Allogene's commitment to keeping stakeholders informed about its off-the-shelf CAR T cell therapy products.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced its participation in three upcoming investor conferences in November and December 2026: the UBS Global Biopharma Conference, the Jefferies Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. The clinical-stage biotechnology company develops allogeneic CAR T products for cancer and autoimmune diseases. Webcasts of presentations will be available on the company's website.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced its participation in several upcoming investor conferences in November and December 2026, including the UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Piper Sandler 38th Annual Healthcare Conference. The company, a clinical-stage biotechnology firm, is focused on developing allogeneic CAR T products for cancer and autoimmune diseases. Webcasts of presentations will be available on Allogene's investor relations website.
Allogene Therapeutics CFO Geoffrey Parker sells $48,698 in stock
Allogene Therapeutics CFO Geoffrey Parker sold 36,342 shares of company stock worth $48,698 on October 21, 2026. This transaction was for tax withholding related to restricted stock unit vesting, not a discretionary trade. The stock is currently trading near its 52-week low, but InvestingPro suggests it is undervalued, and Citizens has reaffirmed a "Market Outperform" rating based on positive clinical trial progress.
Form 4 Allogene Therapeutics Inc: Geoffrey M. Parker (CFO) For: 21 October
This article reports on a Form 4 filing for Allogene Therapeutics Inc, specifically detailing the activities of its CFO, Geoffrey M. Parker, for October 21. Form 4 filings are used to disclose transactions made by company insiders. The article indicates this is a standard disclosure without providing further details on the nature of the transaction.
Allogene Therapeutics CFO Geoffrey Parker sells $48,698 in stock By Investing.com
Allogene Therapeutics CFO Geoffrey Parker sold 36,342 shares of the company's common stock for $48,698 to cover tax withholding obligations. The sale occurred on October 21, 2026, with shares priced at $1.34 each. Following this transaction, Parker directly holds 1,045,877 shares, and the stock is currently trading near its 52-week low, though InvestingPro suggests it is undervalued.
Form 4 Allogene Therapeutics Inc: Geoffrey M. Parker (CFO) For: 21 October
This article reports on a Form 4 filing for Allogene Therapeutics Inc, indicating activity by Chief Financial Officer Geoffrey M. Parker related to October 21st. The filing pertains to insider trading details for the company, whose stock symbol is ALLO. The article provides minimal details beyond the announcement of the filing itself.
Allogene Therapeutics, Inc. Estimates – NASDAQ:ALLO
This article from TradingView provides an overview of Allogene Therapeutics, Inc. (NASDAQ: ALLO) financial data and analyst estimates. It highlights features like income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The platform also offers tools to visualize financial trends over time.
To cover vesting-related taxes, Allogene Therapeutics (ALLO) CFO sells 36,342 shares.
Allogene Therapeutics' Chief Financial Officer, Geoffrey M. Parker, sold 36,342 common shares on October 21, 2026, at $1.34 per share. This sale was not a discretionary trade but was mandated to cover tax withholding obligations tied to the vesting of restricted stock units under the company's equity incentive plan. Following the transaction, Parker's reported holdings were 1,045,877 shares, reflecting previous forfeitures and acquisitions through an employee stock purchase program.
Form 144 Allogene Therapeutics For: 21 October By Investing.com
This article from Investing.com announces the Form 144 filing for Allogene Therapeutics (ALLO) for October 21. It provides a brief mention of the filing and includes the current stock performance of ALLO, which is listed at 0.00%. The article primarily serves as a notification of the filing, with a focus on financial market data.
An officer proposes selling 36,342 Allogene Therapeutics (NASDAQ: ALLO) shares after stock vesting.
Allogene Therapeutics officer Geoffrey M. Parker has proposed selling 36,342 common shares, valued at approximately $48,698.28, following the vesting of 100,000 restricted stock units on October 20, 2026. The proposed sale is scheduled for October 21, 2026, through Morgan Stanley Smith Barney LLC on Nasdaq. This transaction is detailed in a Form 144 SEC filing, indicating the officer's intent to sell a portion of recently acquired shares.
Form 144 Allogene Therapeutics For: 21 October By Investing.com
This article reports on a Form 144 filing for Allogene Therapeutics, specifically for October 21st. It highlights that the company's stock, ALLO, experienced a -2.63% change. The content appears to be a brief announcement of the filing rather than an in-depth analysis.
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value
The article suggests that insiders who sold Allogene Therapeutics (ALLO) stock in the past year, particularly at prices lower than the current market value, might regret their decision. Despite a 4.6% share price increase in the last week, the stock remains down 41% over the past year, and the average insider selling price was above the current market price. This indicates a potential undervaluation or a belief by insiders that the stock may not recover significantly.
We're Not Very Worried About Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Rate
Allogene Therapeutics (NASDAQ:ALLO) is managing its cash burn effectively, with a cash runway of about 3.2 years based on its last reported balance sheet from June 2026. Analysts forecast the company will reach free cash flow breakeven in approximately 3 years, suggesting it should not need to raise additional cash. The company has also reduced its cash burn by 41% over the last year, indicating prudent financial management despite not generating significant revenue yet.
At $1.55 a share, TPG funds sold Allogene Therapeutics (ALLO) stock.
TPG Funds, specifically TPG Carthage Holdings, L.P. and The Rise Fund Carthage, L.P., sold a total of 18,716,306 shares of Allogene Therapeutics (ALLO) common stock at $1.55 per share on September 28, 2026. Following this sale, TPG GP A, LLC, James G. Coulter, and Jon Winkelried reported that they no longer beneficially own any shares and have ceased to be beneficial owners of more than 5% of the company's stock. This transaction signifies a complete divestment by these reporting persons from Allogene Therapeutics.
Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Sep 2026 $ALLO
Allogene Therapeutics (ALLO) had a short interest of 59.60 million shares as of September 15, 2026, representing 19.87% of its public float, an increase of 0.82% from the previous report. The short interest ratio is 11.3 days to cover. This data indicates a significant level of bearish sentiment among investors towards ALLO.
Allogene Therapeutics Inc. (ALLO) Peer Comparison – Compare with Others
This article provides a detailed peer comparison for Allogene Therapeutics Inc. (ALLO), evaluating its financial metrics against several other biotechnology and healthcare companies. Key data points such as market cap, revenue, net profit, various ratios (P/E, P/B, RoE), and growth metrics are presented, allowing investors to assess ALLO's performance relative to its industry peers. The comparison covers income statements, liabilities, assets, cash flow, profitability, growth, valuation, solvency, and operating efficiency ratios.
Citizens reiterates Allogene stock rating on CAR T pipeline progress
Citizens has reiterated its Market Outperform rating and $6.00 price target on Allogene Therapeutics Inc. (NASDAQ:ALLO), citing the biotechnology company's progress in its CAR T pipeline. The stock is currently trading at $1.78 and is considered undervalued according to InvestingPro analysis. Allogene recently reported a successful interim futility analysis for its pivotal ALPHA3 trial and a narrower-than-expected loss for Q2 2026, alongside a $200 million public offering.
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) shares have dropped 11.1% since its last earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 13 cents per share in Q2 2026, with nil sales, and has extended its cash runway into 2029. Despite upward trending estimates and a Zacks Rank #3 (Hold), the stock faces questions about its ability to rebound.
Allogene at Citi summit: mrD strategy and cash runway in focus
Allogene Therapeutics (ALLO) presented its minimal residual disease (MRD) strategy and financial runway at Citi's Biopharma Back to School Summit. CEO Zach Roberts highlighted strong clinical momentum for cema-cel in lymphoma and ALLO-329 in autoimmune disease, while also emphasizing early commercial preparation. The company reported $420 million in cash, providing a runway into 2029 to cover key clinical milestones and data releases.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Allogene Therapeutics announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Mr. Parker will continue to lead the finance organization during the search for his successor. The company praised his leadership during a pivotal period and expressed confidence in Allogene's strategy and pipeline.
Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026
Allogene Therapeutics, Inc. has announced that its Chief Financial Officer, Geoffrey Parker, will retire on November 6, 2026. Parker will continue to lead the finance department until his retirement date, while the company searches for his replacement.
Allogene Therapeutics CFO Geoffrey Parker to Retire
Allogene Therapeutics, Inc. announced that its Chief Financial Officer, Geoffrey Parker, will retire from his position effective November 6, 2026. Parker also serves as the Executive Vice President and Principal Financial Officer for the biotechnology company. This news was released on September 2, 2026.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Allogene Therapeutics announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire on November 6, 2026. Parker will continue to lead the finance organization during the search for his successor. CEO Zachary Roberts praised Parker's leadership, and Parker expressed confidence in Allogene's strategy and pipeline.
Allogene Therapeutics to present pipeline and strategy updates at fall investor conferences
Allogene Therapeutics is set to present updates on its investigational pipeline and corporate strategy at upcoming fall investor conferences. The company, a leader in cell therapy, will make webcasts of these presentations available on its website. This follows recent Q2 2026 updates highlighting progress in allogeneic cell therapy programs and a new strategy to prevent relapse in LBCL patients.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, a clinical-stage biotechnology company, announced its participation in the upcoming Citi Biopharma Back to School Conference. The company will present on Wednesday, September 9, at 5:00 a.m. PT/8:00 a.m. ET, with webcasts and replays available on its investor relations website. Allogene is focused on developing allogeneic CAR T products for cancer and autoimmune diseases.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced its participation in the upcoming Citi Biopharma Back to School Conference on September 9, 2026. The clinical-stage biotechnology company, focused on allogeneic CAR T products for cancer and autoimmune diseases, will present at 5:00 a.m. PT/8:00 a.m. ET. Webcasts of the presentation will be available on the company's website under the Investors tab.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, Inc. announced its participation in the upcoming Citi Biopharma Back to School Conference on September 9, 2026, at 5:00 a.m. PT/8:00 a.m. ET. The clinical-stage biotechnology company, focused on developing allogeneic CAR T products for cancer and autoimmune diseases, will post any available webcasts on its investor relations website. A replay of the conference will be available for approximately 30 days following the live webcast.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced its participation in the upcoming Citi Biopharma Back to School Conference on September 9, 2026. The company will present at 5:00 a.m. PT/8:00 a.m. ET, with webcasts and replays available on its investor relations website. Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T products for cancer and autoimmune disease.
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? (ALLO)
Allogene Therapeutics' cema-cel showed significant early biological activity in clinical trials, achieving MRD clearance in 58.3% of patients and a 97.7% median ctDNA reduction by day 45. While FDA designations like RMAT and Fast Track support its development, durable efficacy is yet to be proven. Despite risks, a speculative "Buy" rating is suggested due to a potential 61% upside to a $3.50 fair-value estimate.
Allogene (NASDAQ: ALLO) exec share sale is tax ‘sell to cover’
Allogene Therapeutics (NASDAQ: ALLO) SVP and General Counsel, Douglas Earl Martin, sold 29,697 shares of common stock at $2.12 per share on August 21, 2026. This sale was a non-discretionary "sell to cover" transaction to satisfy tax withholding obligations related to the vesting of restricted stock units. After this transaction and other adjustments, Martin directly holds 488,267 shares of Allogene common stock.
Allogene (NASDAQ: ALLO) exec plans sale of 29,697 shares
Allogene Therapeutics, Inc. officer Douglas Earl Martin has filed a notice under Rule 144 to sell up to 29,697 shares of common stock, valued at $62,957.64, through Morgan Stanley Smith Barney LLC on or after August 21, 2026. These shares are part of a restricted stock unit award, with 81,719 shares vesting on August 20, 2026, as part of the company's equity compensation plan. The filing indicates a neutral impact and sentiment for the company.
Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026)
This article reports on an SEC filing by Allogene Therapeutics, Inc. (ALLO) dated August 21, 2026. The filing, a Form S-3, became effective on August 20, 2026, at 4:00 P.M. The article also provides a brief overview of the company's recent news and SEC filings, highlighting its market performance and a recent FDA RMAT designation.
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
This article analyzes Allogene Therapeutics (NASDAQ:ALLO) and suggests it is in a strong financial position to invest in growth. It likely reviews the company's financial health, market performance, or strategic advantages that enable such investments. The analysis indicates a positive outlook regarding the company's capacity for future development.